Cannabinoid modulation of drug reward and the implications of marijuana legalization Dan P. Covey, Jennifer M. Wenzel, and Joseph F. Cheer Brain Research, 2015 1628, 233–243. doi : 10.1016/j.brainres.2014.11.034. Abstract Marijuana is the most popular illegal drug worldwide. Recent trends indicate that this may soon change; not due to decreased marijuana use, but to an amendment in marijuana’s illegal status. The cannabinoid type 1 (CB1) receptor mediates marijuana’s psychoactive and reinforcing properties. CB1 receptors are also part of the brain endocannabinoid (eCB) system and support numerous forms of learning and memory, including the conditioned reinforcing properties of cues predicting reward or punishment. This is accomplished [...]
Lire la suiteCannabinoids, Pain, and Opioid Use Reduction : The Importance of Distilling and Disseminating Existing Data Kent E. HUTCHISON, Sarah L. HAGERTY, Jeffrey GALINKIN, Angela D. BRYAN, L. Cinnamon BIDWELL Cannabis and Cannabinoid Research, 2019, 4, (3), 158-164. Doi : 10.1089/can.2018.0052 Abstract The high prevalence of chronic pain conditions combined with an over-reliance on opioid prescriptions has resulted in an opioid epidemic and a desperate need for solutions. There is some debate about whether cannabis might play a role in addressing chronic pain conditions as well as the opioid epidemic. Recent surveys suggest that a large number of people are using cannabis as a treatment for [...]
Lire la suiteUse and Reported Helpfulness of Cannabinoids Among Primary Care Patients in Vermont Nicole Wershoven, Amanda G. Kennedy, and Charles D. MacLean Journal of Primary Care and Community Health, 2020, 11, 1-6. Doi : 10.1177/2150132720946954 Abstract Introduction : While cannabis has been medically legal in Vermont since 2004 and recreationally legal since 2018 there has been minimal published research regarding the use and practices in the adult population. This gap in understanding results in primary care providers having difficulty navigating conversations surrounding cannabinoid use. The purpose of this research was to identify current use and perceptions of cannabinoids, including Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in adult [...]
Lire la suiteFDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression Megan Brooks Medscape Medical News © 2019 November 25, 2019 The US Food and Drug Administration (FDA) has granted the Usona Institute breakthrough therapy designation for psilocybin for the treatment of major depressive disorder (MDD). This marks the second time the FDA has granted breakthrough designation for psilocybin, the psychoactive ingredient in "magic mushrooms." In October 2018, Compass Pathways received the designation to test the safety and efficacy of psilocybin-assisted therapy for treatment-resistant depression, as reported by Medscape Medical News. "The results from previous studies clearly demonstrate the remarkable potential for psilocybin as a treatment in MDD patients, which Usona is [...]
Lire la suiteCannabis : An Emerging Treatment for Common Symptoms in Older Adults Kevin H. Yang, BS; Christopher N. Kaufmann, PhD, MHS; Reva Nafsu, LVN; Ella T. Lifset; Khai Nguyen, MD, MHS; Michelle Sexton, ND; Benjamin H. Han, MD, MPH; Arum Kim, MD; Alison A. Moore, MD, MPH Journal of American Geriatric Society, 2021, 69, (1), 91-97. https://www.medscape.com/viewarticle/945238 Abstract and Introduction Abstract Background/Objectives: Use of cannabis is increasing in a variety of populations in the United States; however, few investigations about how and for what reasons cannabis is used in older populations exist. Design: Anonymous survey. Setting: Geriatrics clinic. Participants: A total of 568 adults 65 years and older. Intervention: Not applicable. Measurements: [...]
Lire la suiteMind Menders: The Future of Psychedelics for Mental Illness Batya Swift Yasgur MA, LSW Medscape.com, November 10, 2020 https://www.medscape.com/viewarticle/940749?nlid=138288_425&src=WNL_mdplsfeat_201117_mscpedit_psyc&uac=292598PZ&spon=12&impID=2682236&faf=1 After a 50-year hiatus, psychedelic drugs are undergoing a research renaissance. Agents including psilocybin, methylenedioxymethamphetamine (MDMA), and others are all under investigation to treat a variety of psychiatric illnesses. Medscape spoke with Roland R. Griffiths, professor in the Departments of Psychiatry and Neuroscience and the Oliver Lee McCabe III Professor in the Neuropsychopharmacology of Consciousness, and director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University, Baltimore, Maryland, to discuss the status of these drugs in the United States and their therapeutic potential. Griffiths: Classic psychedelics are [...]
Lire la suiteTrajectories of Nicotine and Cannabis Vaping and Polyuse. From Adolescence to Young Adulthood H. Isabella Lanza, PhD; Jessica L. Barrington-Trimis, PhD; RobMcConnell, MD; Junhan Cho, PhD; Jessica L. Braymiller, PhD; Evan A. Krueger, PhD, MPH, MSW; Adam M. Leventhal, PhD JAMA Network Open, 2020, 3, (10), :e2019181. doi : 10.1001/jamanetworkopen.2020.19181 Abstract IMPORTANCE : Little is known about cannabis vaping trajectories across adolescence and young adulthood or the co-occurrence with nicotine vaping. OBJECTIVE : To evaluate nicotine vaping and cannabis vaping trajectories from late adolescence to young adulthood (18 years of age) and the extent of polysubstance vaping. DESIGN, SETTING, AND PARTICIPANTS : In this prospective cohort study, 5 surveys [...]
Lire la suiteAdolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler Drug and Alcohol Dependence, 2020, 210, 107960 Doi : 10.1016/j.drugalcdep.2020.107960 A B S T R A C T Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008–2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12–17 were used to model state treatment [...]
Lire la suiteAdolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington Jeremy Mennis, Gerald J Stahler Drug and Alcohol Dependence, 2020 May 1, 210, 107960. doi : 10.1016/j.drugalcdep.2020.107960 Abstract Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008-2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12-17 were used to model state treatment admissions trends. [...]
Lire la suiteCannabis Misconceptions Still Common Among MS Clinicians Nancy Melville June 05, 2020 https://www.medscape.com/viewarticle/931872?nlid=135873_425&src=WNL_mdplsfeat_200609_mscpedit_psyc&uac=292598PZ&spon=12&impID=2413707&faf=1 Despite the ever-increasing acceptance of medical cannabis and its notably common use in patients with multiple sclerosis (MS), clinicians treating those patients still may be poorly informed about risks, benefits, regulations, and proper uses, experts say. "There is evidence of a 'clinical void,' with clinicians on one side and people with MS and other conditions on the other that doesn't usually exist regarding therapies that people with MS are using," said Allen C. Bowling, MD, PhD, director of the NeuroHealth Institute and clinical professor of neurology at the University of Colorado, in Aurora. His [...]
Lire la suite